The wide availability of long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) fixed-dose combinations (FDCs) in the absence of head-to-head comparative pragmatic trials makes it difficult to choose which combination should be used. Therefore, we carried out a systematic review with meta-analysis that incorporated the data from trials lasting at least 3 months to evaluate the effectiveness of LAMA/LABA FDCs for COPD treatment.
Calzetta, L., Rogliani, P., Matera, M., Cazzola, M. (2016). A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. CHEST, 149(5), 1181-1196 [10.1016/j.chest.2016.02.646].
A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD
ROGLIANI, PAOLA;CAZZOLA, MARIO
2016-01-01
Abstract
The wide availability of long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) fixed-dose combinations (FDCs) in the absence of head-to-head comparative pragmatic trials makes it difficult to choose which combination should be used. Therefore, we carried out a systematic review with meta-analysis that incorporated the data from trials lasting at least 3 months to evaluate the effectiveness of LAMA/LABA FDCs for COPD treatment.| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0012369216012666-main.pdf
solo utenti autorizzati
Tipologia:
Versione Editoriale (PDF)
Licenza:
Copyright dell'editore
Dimensione
695.74 kB
Formato
Adobe PDF
|
695.74 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
